连花清瘟颗粒联合奥司他韦治疗儿童流感病毒感染的疗效及安全性研究

Efficacy and Safety of Lianhua Qingwen Granule Combined with Oseltamivir in the Treatment of Influenza Virus Infection in Children

目的:探究儿童流感病毒感染采用连花清瘟颗粒联合奥司他韦治疗的临床疗效及安全性。方法:选取我院2019年1月—12月收治的97例流感病毒感染患儿为研究对象,按照随机数字表法分为两组,对照组(n=48)仅采用奥司他韦治疗,观察组(n=49)采用连花清瘟颗粒联合奥司他韦治疗,对比两组临床疗效、症状改善时间、炎症指标与不良反应发生情况。结果:治疗后,与对照组比较,观察组总有效率为93.88%,高于对照组的75.00%(P<0.05);观察组各项症状改善时间均更短(P<0.05);观察组C反应蛋白(CRP)、降钙素原(PCT)、血清淀粉样蛋白A(SAA)水平更低(P<0.05);观察组不良反应发生率为10.20%,与对照组(8.33%)比较差异无统计学意义(P>0.05)。结论:儿童流感病毒感染采用连花清瘟颗粒联合奥司他韦治疗效果显著,安全性高,利于改善临床症状,减轻机体炎症反应。

Objective:To explore the clinical efficacy and safety of Lianhua Qingwen granule combined with oseltamivir in the treatment of influenza virus infection in children.Methods:97 cases of influenza virus infection in our hospital from January to December 2019 were selected as the study objects.According to the random number table method,they were divided into two groups.The control group(n=48)was only treated with oseltamivir,and the observation group(n=49)was treated with Lianhua Qingwen granule combined with oseltamivir.The clinical effect,symptom improvement time,inflammation indexes and adverse reactions of the two groups were compared.Results:The total effective rate of the observation group was 93.88%,higher than 75.00%of the control group(P<0.05);compared with the control group,the improvement time of symptoms in the observation group was shorter(P<0.05);compared with the control group,the level of C-reactive protein(CRP),procalcitonin(PCT),serum amyloid A(SAA)in the observation group was lower(P<0.05);The incidence of adverse reactions in the observation group was 10.20%,and there was no significant difference compared with 8.33%in the control group(P>0.05).Conclusion:The clinical efficacy of Lianhua Qingwen granule combined with oseltamivir in the treatment of influenza virus infection in children is significant,with high safety,which is conducive to improving the clinical symptoms and reducing the body's inflammatory response.